Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Research Reports for Pfizer, Royal Dutch Shell & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Royal Dutch Shell (RDS.A) and Celgene (CELG).
Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
by Zacks Equity Research
Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.
Spero Gets Fast Track Designation for SPR994, Shares Improve
by Zacks Equity Research
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
Global Blood Focuses on Developing Lead Candidate Voxelotor
by Zacks Equity Research
Global Blood (GBT) is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
by Zacks Equity Research
Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.03, moving -0.92% from the previous trading session.
Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
by Zacks Equity Research
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
by Zacks Equity Research
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
by Swarup Gupta
The index traversed yet another volatile week but still managed to notch up strong gains.
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Glaxo Presents Encouraging Data on Endometrial Cancer Drug
by Zacks Equity Research
Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.32, moving +1.22% from the previous trading session.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J